<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="201">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01440595</url>
  </required_header>
  <id_info>
    <org_study_id>5172-012</org_study_id>
    <nct_id>NCT01440595</nct_id>
  </id_info>
  <brief_title>Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012 AM1)</brief_title>
  <official_title>A Randomized, Partially Double-Blind, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Pegylated-Interferon and Ribavirin in Treatment-Naive Patients With Chronic Genotype 2 or 3 Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and antiviral activity of grazoprevir
      (MK-5172) when administered concomitantly with peginterferon alfa-2b (Peg-IFN) and ribavirin
      (RBV) to treatment-naïve participants with chronic genotype 2 (GT2) or genotype 3 (GT3)
      hepatitis C virus (HCV) infections.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants achieving complete early virologic response (cEVR) in the grazoprevir treatment arms</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first achievement of undetectable HCV ribonucleic acid (RNA)</measure>
    <time_frame>Baseline to Week 12 for Grazoprevir treatment arms, Week 24 for Placebo arm</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving rapid viral response (RVR)</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving sustained viral response 12 weeks after completion of therapy (SVR12)</measure>
    <time_frame>Week 24 for Grazoprevir treatment arms, Week 36 for Placebo arm</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving sustained viral response 24 weeks after completion of therapy (SVR24)</measure>
    <time_frame>Week 36 for Grazoprevir treatment arms, Week 48 for Placebo arm</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving undetectable HCV RNA at Week 12 in the Placebo arm</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving complete early virologic response (cEVR) at Week 24 in the Placebo arm</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Grazoprevir 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazoprevir 200 mg in combination with Peg-IFN and RBV for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grazoprevir 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazoprevir 400 mg in combination with Peg-IFN and RBV for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grazoprevir 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazoprevir 800 mg in combination with Peg-IFN and RBV for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to Grazoprevir in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grazoprevir</intervention_name>
    <description>Grazoprevir once daily for 12 weeks</description>
    <arm_group_label>Grazoprevir 200 mg</arm_group_label>
    <arm_group_label>Grazoprevir 400 mg</arm_group_label>
    <arm_group_label>Grazoprevir 800 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Grazoprevir</intervention_name>
    <description>Placebo to Grazoprevir once daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2b (Peg-IFN)</intervention_name>
    <description>Peg-IFN weekly subcutaneous injection at 1.5 mcg/kg/week for 12 or 24 weeks</description>
    <arm_group_label>Grazoprevir 200 mg</arm_group_label>
    <arm_group_label>Grazoprevir 400 mg</arm_group_label>
    <arm_group_label>Grazoprevir 800 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PegIntron®, SCH 054031</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Ribavirin twice daily at a dose of 600 mg to 1400 mg based on weight for 12 or 24 weeks</description>
    <arm_group_label>Grazoprevir 200 mg</arm_group_label>
    <arm_group_label>Grazoprevir 400 mg</arm_group_label>
    <arm_group_label>Grazoprevir 800 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Rebetol®, SCH 018908</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight ≥ 88 lbs and ≤ 275 lbs

          -  Documented CHC GT2 or GT3 infection

          -  No known cirrhosis

          -  Agrees to use two acceptable methods of birth control during study and through 6
             months after last dose of study drug

          -  Chest X-ray within the last 6 months

          -  Eye exam within the last 6 months

        Exclusion Criteria:

          -  Known to be human immunodeficiency virus (HIV) positive or co-infected with active
             hepatitis B virus (positive for Hepatitis B surface antigen)

          -  Prior approved or investigational treatment for hepatitis C

          -  Evidence of hepatocellular carcinoma

          -  Diabetic and/or high blood pressure with clinically significant eye exam findings

          -  Pre-existing psychiatric condition

          -  Clinical diagnosis of abuse of certain substances within specified timeframes

          -  Known medical condition that could interfere with participation

          -  Active or suspected cancer within the last 5 years

          -  Female who is pregnant, breastfeeding, or expecting to conceive or donate eggs

          -  Male who is planning to impregnate partner or donate sperm

          -  Male with a pregnant female partner

          -  Chronic hepatitis not caused by HCV
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Italy</country>
    <country>Norway</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2014</verification_date>
  <lastchanged_date>November 9, 2014</lastchanged_date>
  <firstreceived_date>September 22, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
